| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a3d936df6b0ad9a42c3f0a386f84015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_33c33c9854af5f58d16ff7b2c305e037
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90759d4a2d9f26db53ac628d5dcd86cd |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-30 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-91 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N11-02 |
| filingDate |
2000-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2084b383fe4722bb5a8220a8259c3f2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4aeffe30bc3011c0a7c707d92dc40ea0 |
| publicationDate |
2000-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0061156-A2 |
| titleOfInvention |
Methods of treating schizophrenia |
| abstract |
The invention provides methods for the treatment of abnormal psychiatric states, particularly the negative symptoms of schizophrenia and extrapyramidal side effects (EPS) of antipsychotic drugs. The inventive methods relate to the administration of therapeutic cells (which produce dopamine or dopamine precursors) adhered to support matrices to subjects suffering from the negative symptoms of schizophrenia and/or EPS. The therapeutic cells may be coadministered with cells which protect the therapeutic cells from immune rejection and/or cells which produce neurotrophic factors which improve the viability of the therapeutic cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2004108144-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004108144-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-4563937-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03013521-A1 |
| priorityDate |
1999-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |